Choice of various Antiplatelets and Anticoagulants in secondary prevention in patients of acute ischemic stroke

Stroke was defined according to World Health Organization (WHO) recommendations as rapidly developing clinical symptoms and/or signs of focal, and at times global, loss of cerebral function, with symptoms lasting more than 24 h or leading to death, with no apparent cause other than that of vascular origin. Stroke is a heterogeneous disease with different etiology and outcomes, thus it is prudent to define these factors in making decisions in the initial management and also in planning secondary prevention strategies. A well-organized stroke data bank can help to provide much information and numerous insights into these problems. Stroke and ischemic heart disease are among the most common causes of death and disability in the world. Worldwide, stroke is the second most common cause of mortality and the third most common cause of disability. According to World Health Organization (WHO), stroke has caused about 5.54 million deaths worldwide in 1999 with two-thirds of these deaths occurring in less developed countries. Stroke is also the most common neurological condition causing long-term disability and has enormous emotional and socioeconomic consequences in patients.